The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia

References

• Kumar NB , KaziA, SmithTet al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr. Treat. Options Oncol.11(3–4), 107–117 (2010).
   PubMed Web of Science ®Google Scholar
• von Haehling S , AnkerSD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J. Cachexia Sarcopenia Muscle1(1), 1–5 (2010).
   PubMed Web of Science ®Google Scholar
• Fearon K , StrasserF, AnkerSDet al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol.12(5), 489–495 (2011).
   PubMed Web of Science ®Google Scholar
• Fearon KC , VossAC, HusteadDS, Cancer Cachexia Study Group. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am. J. Clin. Nutr.83(6), 1345–1350 (2006).
   PubMed Web of Science ®Google Scholar
• Evans WJ , MorleyJE, ArgilésJet al. Cachexia: a new definition. Clin. Nutr.27(6), 793–799 (2008).
   PubMed Web of Science ®Google Scholar
• Muscaritoli M , MolfinoA, LuciaS, Rossi FanelliF. Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach. Crit. Rev. Oncol. Hematol.94(2), 251–259 (2015).
   PubMed Web of Science ®Google Scholar
• Tisdale MJ . Mechanisms of cancer cachexia. Physiol. Rev.89(2), 381–410 (2009).
   PubMed Web of Science ®Google Scholar
• Argilés JM , AnkerSD, EvansWJet al. Consensus on cachexia definitions. J. Am. Med. Dir. Assoc.11(4), 229–230 (2010).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , ArendsJ. The causes and consequences of cancer-associated malnutrition. Eur. J. Oncol. Nurs.9(Suppl. 2), S51–S63 (2005).
   PubMedGoogle Scholar
• Dahele M , SkipworthRJ, WallL, VossA, PrestonT, FearonKC. Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. J. Pain Symptom Manage.33(6), 676–685 (2007).
   PubMed Web of Science ®Google Scholar
• Ferriolli E , SkipworthRJ, HendryPet al. Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy? J. Pain Symptom Manage. 43(6), 1025–1035 (2012).
   PubMed Web of Science ®Google Scholar
• Arrieta O , Michel OrtegaRM, Villanueva-RodríguezGet al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer10, 50 (2010).
   PubMed Web of Science ®Google Scholar
• Aapro M , ArendsJ, BozzettiFet al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann. Oncol.25(8), 1492–1499 (2014).
   PubMed Web of Science ®Google Scholar
• Andreyev HJN , NormanAR, OatesJ, CunninghamD. Why do patients with weight loss have worse outcomes when undergoing chemotherapy for gastrointestinal malignancies?Eur. J. Cancer34(4), 503–509 (1998).
   PubMed Web of Science ®Google Scholar
• Costa G , DonaldsonSS. Current concepts in cancer: effects of cancer and cancer treatment on the nutrition of the host. N. Engl. J. Med.300(26), 1471–1474 (1979).
   PubMed Web of Science ®Google Scholar
• Maltoni M , NanniO, PirovanoMet al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J. Pain Symptom Manage.17(4), 240–247 (1999).
   PubMed Web of Science ®Google Scholar
• Currow DC , AbernethyAP. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol.10(5), 789–802 (2014).
   PubMed Web of Science ®Google Scholar
• International Alliance of Patients’ Organizations . What is Patient-Centred Healthcare? A Review of Definitions and Principles. International Alliance of Patients’ Organizations, London, UK, 1–34 (2007).
   Google Scholar
• Hopkinson JB . Psychosocial impact of cancer cachexia. J. Cachexia Sarcopenia Muscle5(2), 89–94 (2014).
   PubMed Web of Science ®Google Scholar
• Wheelwright SJ , JohnsonCD. Patient-reported outcomes in cancer cachexia clinical trials. Curr. Opin. Support. Palliat. Care9(4), 325–332 (2015).
   PubMed Web of Science ®Google Scholar
• Kluetz PG , SlagleA, PapadopoulosEJet al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin. Cancer Res.22(7), 1553–1558 (2016).
   PubMed Web of Science ®Google Scholar
• Robinson DW , EisenbergDF, CellaDet al. The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J. Support. Oncol.6(6), 283–290 (2008).
   PubMedGoogle Scholar
• Hopkinson JB . Carers’ influence on diets of people with advanced cancer. Nurs. Times104(12), 28–29 (2008).
   Google Scholar
• Deshpande PR , RajanS, SudeepthiBL, Abdul NazirCP. Patient-reported outcomes: a new era in clinical research. Perspect. Clin. Res.2(4), 137–144 (2011).
   PubMedGoogle Scholar
• Fearon KC , SkipworthRJ. A critical assessment of the outcome measures and goals of intervention in cancer cachexia. In: Cachexia and Wasting: A Modern Approach. MantovaniG ( Ed.). Springer, Milan, Italy, 619–630 (2006).
   Google Scholar
• Blauwhoff-Buskermolen S , RuijgrokC, OsteloRWet al. The assessment of anorexia in patients with cancer: cut-off values for the FAACT-A/CS and the VAS for appetite. Support. Care Cancer24(2), 661–666 (2016).
   PubMed Web of Science ®Google Scholar
• Aaronson NK , AhmedzaiS, BergmanBet al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst.85(5), 365–376 (1993).
   PubMed Web of Science ®Google Scholar
• Ribaudo JM , CellaD, HahnEAet al. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual. Life Res.9(10), 1137–1146 (2000).
   PubMed Web of Science ®Google Scholar
• LeBlanc TW , SamsaGP, WolfSP, LockeSC, CellaDF, AbernethyAP. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS). Support. Care Cancer23(8), 2341–2347 (2015).
   PubMed Web of Science ®Google Scholar
• Fearon K , ArgilesJM, BaracosVEet al. Request for regulatory guidance for cancer cachexia intervention trials. J. Cachexia Sarcopenia Muscle6(4), 272–274 (2015).
   PubMed Web of Science ®Google Scholar
• Mantovani G , MaccioA, MadedduCet al. Randomized Phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist15(2), 200–211 (2010).
   PubMed Web of Science ®Google Scholar
• Baldwin C , SpiroA, AhernR, EmeryPW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J. Natl Cancer Inst.104(5), 371–385 (2012).
   PubMedGoogle Scholar
• Gould DW , LahartI, CarmichaelAR, KoutedakisY, MetsiosGS. Cancer cachexia prevention via physical exercise: molecular mechanisms. J. Cachexia Sarcopenia Muscle4(2), 111–124 (2013).
   PubMed Web of Science ®Google Scholar
• Grande AJ , SilvaV, MaddocksM. Exercise for cancer cachexia in adults: executive summary of a Cochrane Collaboration systematic review. J. Cachexia Sarcopenia Muscle6(3), 208–211 (2015).
   PubMed Web of Science ®Google Scholar
• Berenstein G , OrtizZ. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. (2), CD004310 (2005).
   PubMed Web of Science ®Google Scholar
• Lee SJ , GlassDJ. Treating cancer cachexia to treat cancer. Skelet. Muscle1(1), 2 (2011).
   PubMedGoogle Scholar
• Loprinzi CL , KuglerJW, SloanJAet al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J. Clin. Oncol.17(10), 3299–3306 (1999).
   PubMed Web of Science ®Google Scholar
• Sampaio EP , SarnoEN, GalillyR, CohnZA, KaplanG. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med.173(3), 699–703 (1991).
   PubMed Web of Science ®Google Scholar
• Gordon JN , GogginPM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad. Med. J.79(929), 127–132 (2003).
   PubMed Web of Science ®Google Scholar
• Lundholm K , DanerydP, KörnerU, HyltanderA, BosaeusI. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int. J. Oncol.24(3), 505–512 (2004).
   PubMed Web of Science ®Google Scholar
• Mantovani G , MacciòA, MadedduCet al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J. Mol. Med. (Berl.)88(1), 85–92 (2010).
   PubMed Web of Science ®Google Scholar
• Fearon KC , BarberMD, MosesAGet al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J. Clin. Oncol.24(21), 3401–3407 (2006).
   PubMed Web of Science ®Google Scholar
• McCarthy HD , CrowderRE, DrydenS, WilliamsG. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur. J. Pharmacol.265(1–2), 99–102 (1994).
   PubMed Web of Science ®Google Scholar
• Ruiz Garcia V , López-BrizE, Carbonell SanchisR, Gonzalvez PeralesJL, Bort-MartiS. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. (3), CD004310 (2013).
   PubMed Web of Science ®Google Scholar
• Inui A . Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J. Clin.52(2), 72–91 (2002).
   PubMed Web of Science ®Google Scholar
• Gordon JN , TrebbleTM, EllisRDet al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut54(4), 540–545 (2005).
   PubMed Web of Science ®Google Scholar
• Davenport AP , BonnerTI, FoordSMet al. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol. Rev.57(4), 541–546 (2005).
   PubMed Web of Science ®Google Scholar
• Lundholm K , GunneboL, KörnerUet al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer116(8), 2044–2052 (2010).
   PubMed Web of Science ®Google Scholar
• Temel JS , AbernethyAP, CurrowDCet al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, Phase III trials. Lancet Oncol.17(4), 519–531 (2016).
   PubMed Web of Science ®Google Scholar
• Arends J , BachmannP, BaracosVet al. ESPEN guidelines on nutrition in cancer patients. Clin. Nutr.36(1), 11–48 (2017).
   PubMed Web of Science ®Google Scholar
• Dev R , Del FabbroE, BrueraE. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer110(6), 1173–1177 (2007).
   PubMed Web of Science ®Google Scholar
• Anker SD , CoatsAJ, MorleyJE. Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin. J. Cachexia Sarcopenia Muscle6(4), 275–277 (2015).
   PubMed Web of Science ®Google Scholar
• Macciò A , MadedduC, MantovaniG. Current pharmacotherapy options for cancer anorexia and cachexia. Expert Opin. Pharmacother.13(17), 2453–2472 (2012).
   PubMed Web of Science ®Google Scholar
• Currow DC , TemelJS, GiorginoR, AbernethyAP, FriendJ, FearonK. Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (<20 kg/m2): a pooled efficacy data analysis of two Phase III studies. J. Clin. Oncol.34(Suppl.), Abstract 10.19 (2016).
   Google Scholar
• Pietra C , TakedaY, Tazawa-OgataNet al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J. Cachexia Sarcopenia Muscle5(4), 329–337 (2014).
   PubMed Web of Science ®Google Scholar
• Nakazato M , MurakamiN, DateYet al. A role for ghrelin in the central regulation of feeding. Nature409(6817), 194–198 (2001).
   PubMed Web of Science ®Google Scholar
• Williams DL , CummingsDE. Regulation of ghrelin in physiologic and pathophysiologic states. J. Nutr.135(5), 1320–1325 (2005).
   PubMed Web of Science ®Google Scholar
• Delporte C . Structure and physiological actions of ghrelin. Scientifica (Cairo) 2013, 518909 (2013).
   PubMedGoogle Scholar
• Arnold M , MuraA, LanghansW, GearyN. Gut vagal afferents are not necessary for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat. J. Neurosci.26(43), 11052–11060 (2006).
   PubMed Web of Science ®Google Scholar
• Takaya K , AriyasuH, KanamotoNet al. Ghrelin strongly stimulates growth hormone release in humans. J. Clin. Endocrinol. Metab.85(12), 4908–4911 (2000).
   PubMed Web of Science ®Google Scholar
• Kojima M , HosodaH, DateY, NakazatoM, MatsuoH, KangawaK. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature402(6762), 656–660 (1999).
   PubMed Web of Science ®Google Scholar
• Akazimu T , KangawaK. Ghrelin for cachexia. J. Cachexia Sarcopenia Muscle.1(2), 169–176 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang H , GarciaJM. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin. Pharmacother.16(8), 1245–1253 (2015).
   PubMed Web of Science ®Google Scholar
• Jeffery PL , HeringtonAC, ChopinLK. The potential autocrine/paracrine roles of ghrelin and its receptor in hormone-dependent cancer. Cytokine Growth Factor Rev.14(2), 113–122 (2003).
   PubMed Web of Science ®Google Scholar
• Sever S , WhiteDL, GarciaJM. Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review. Endocr. Relat. Cancer23(9), R393–R409 (2016).
   PubMed Web of Science ®Google Scholar
• Northrup R , KurodaK, DuusEMet al. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support. Care Cancer21(9), 2409–2415 (2013).
   PubMed Web of Science ®Google Scholar
• Legakis I , StathopoulosJ, MatzouridisT, StathopoulosGP. Decreased plasma ghrelin levels in patients with advanced cancer and weight loss in comparison to healthy individuals. Anticancer Res.29(10), 3949–3952 (2009).
   PubMed Web of Science ®Google Scholar
• Huang Q , FanYZ, GeBJ, ZhuQ, TuZY. Circulating ghrelin in patients with gastric and colorectal cancer. Dig. Dis. Sci.52(3), 803–809 (2007).
   PubMed Web of Science ®Google Scholar
• Mansson JV , AlvesFD, BioloA, SouzaGC. Use of ghrelin in cachexia syndrome: a systematic review of clinical trials. Nutr. Rev.74(11), 659–669 (2016).
   PubMed Web of Science ®Google Scholar
• Su J , GengJ, BaoJet al. Two ghrelin receptor agonists for adults with malnutrition: a systematic review and meta-analysis. Nutr. J.15(1), 97 (2016).
   PubMedGoogle Scholar
• Laviano A , MeguidMM, InuiA, MuscaritoliM, Rossi-FanelliF. Therapy insight: cancer anorexia-cachexia syndrome--when all you can eat is yourself. Nat. Clin. Pract. Oncol.2(3), 158–165 (2005).
   PubMedGoogle Scholar
• Dewys WD , BeggC, LavinPTet al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med.69(4), 491–497 (1980).
   PubMed Web of Science ®Google Scholar
• Garcia JM , FriendJ, AllenS. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support. Care Cancer21(1), 129–137 (2013).
   PubMed Web of Science ®Google Scholar
• Garcia JM , BocciaRV, GrahamCDet al. Anamorelin for patients with cancer cachexia: an integrated analysis of two Phase II, randomised, placebo-controlled, double-blind trials. Lancet Oncol.16(1), 108–116 (2015).
   PubMed Web of Science ®Google Scholar
• Temel J , BondardeS, JainM, AllenS, MannW. Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized, double-blind, placebo-controlled, multicentre Phase II study. Eur. J. Cancer49(Suppl. 2), Abstract 1308 (2013).
   Google Scholar
• Blum R , PolvinoW. Pharmacokinetic (PK) profile of RC-1291, a novel oral ghrelin mimetic for the treatment of cancer anorexia/cachexia. Support. Care Cancer14(6), Abstract 03–010 (2006).
   Google Scholar
• Kumor K , PolvinoW. Biologic activity of RC-1291, a novel oral ghrelin mimetic for cancer anorexia/cachexia: results from a Phase I randomized, double-blind, placebo-controlled trial in healthy volunteers. Support. Care Cancer14(6), Abstract 03–009 (2006).
   Google Scholar
• Garcia JM , YanY, DuusE, FriendJ. Anamorelin’s effects on appendicular lean body mass in cancer patients with cachexia: results from a Phase II randomized, double blind, multicenter study. Ann. Oncol.23(Suppl. 9), Abstract 1588P (2012).
   Google Scholar
• Takayama K , KatakamiN, YokoyamaTet al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized Phase II trial. Support. Care Cancer24(8), 3495–3505 (2016).
   PubMed Web of Science ®Google Scholar
• Kurihara M , ShimizuH, TsuboiKet al. Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology8(4), 355–363 (1999).
   PubMed Web of Science ®Google Scholar
• Okuyama T , WangXS, AkechiTet al. Japanese version of the MD Anderson Symptom Inventory: a validation study. J. Pain Symptom Manage.26(6), 1093–1104 (2003).
   PubMed Web of Science ®Google Scholar
• Currow D , TemelJ, FearonK, FriendJ, YanY, AbernethyA. ROMANA 3: a safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia. Eur. J. Cancer51(Suppl. 3), Abstract 1603 (2015).
   Google Scholar
• Currow D , TemelJ, AbernethyA, FriendJ, GiorginoR, FearonKC. Pooled efficacy data from ROMANA 1 and ROMANA 2, two Phase III trials of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia. Support. Care Cancer24(Suppl. 1), Abstract PS006 (2016).
   PubMedGoogle Scholar
• Currow D , TemelJ, AbernethyA, FriendJ, GiorginoR, FearonKC. Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and acute phase protein reaction (APPR): pooled analysis of two Phase III trials (ROMANA 1 and ROMANA 2). Ann. Oncol.27(Suppl. 6), Abstract 1446P (2016).
   Google Scholar
• Fearon K , CurrowD, TemelJ, GiorginoR, FriendJ, AbernethyA. Body composition in non-small cell lung cancer (NSCLC) patients with cachexia and improved anorexia-cachexia symptoms: anamorelin Phase III trials pooled analysis. Clin. Nutr.35(Suppl. 1), Abstract OR45 (2016).
   Google Scholar
• Jahn P , CurrowD, TemelJet al. Effects of anamorelin on anorexia-cachexia in advanced non-small cell lung cancer patients: pooled analysis of two Phase III trials (ROMANA 1 and ROMANA 2). Eur. J. Oncol. Nurs. (Suppl.), Abstract (Ahead of print).
   Google Scholar
• Heppner KM , TongJ. Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions. Eur. J Endocrinol.171(1), R21–R32 (2014).
   PubMed Web of Science ®Google Scholar
• Bai Y , HuY, ZhaoYet al. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Support. Care Cancer25(5), 1651–1659 (2017).
   PubMed Web of Science ®Google Scholar
• Hopkinson JB , RichardsonA. A mixed-methods qualitative research study to develop a complex intervention for weight loss and anorexia in advanced cancer: the family approach to weight and eating. Palliat. Med.29(2), 164–176 (2015).
   PubMed Web of Science ®Google Scholar